Standard management options for Rosacea, part 2: Options according to subtype

Cutis

Volumn 84, Issue 2, 2009, Pages 97-104

  Odom, Richard ^a   Dahl, Mark ^b   Dover, Jeffrey ^c   Draelos, Zoe ^d   Drake, Lynn ^e   Macsai, Marian ^f   Powell, Frank ^g   Thiboutot, Diane ^h   Webster, Guy F ⁱ   Wilkin, Jonathan ^j  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MAYO CLINIC   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DERMATOLOGY CONSULTING SERVICES   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^h PENN STATE COLLEGE OF MEDICINE   (United States)

ⁱ THOMAS JEFFERSON UNIVERSITY   (United States)

^j National Rosacea Society Medical Advisory Board   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLASSIFICATION; ERYTHEMA; EYE DISEASE; HOSPITALIZATION; HUMAN; METHODOLOGY; PATHOLOGY; ROSACEA; SKIN CARE; TELANGIECTASIA;

ERYTHEMA; EYE DISEASES; HUMANS; RHINOPHYMA; ROSACEA; SEVERITY OF ILLNESS INDEX; SKIN CARE; TELANGIECTASIS;

EID: 77953944757     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Odom R, Dahl M, Dover J, et al National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. Standard management options for rosacea, part 1: Overview and broad spectrum of care. Cutis. 2009;84:43-47.
2. Wilkin JK. The red face: Flushing disorders. Clin Dermatol. 1993;11:211-223.
3. Jasim ZF, Woo WK, Handley JM. Long-pulsed (6-ms) pulsed dye laser treatment of rosacea-associated telangiectasia using subpurpuric clinical threshold. Dermatol Surg. 2004;30:37-40.
4. Alam M, Dover JS, Arndt KA. Treatment of facial telangiectasia with variable-pulse high-fluence pulsed-dye laser: Comparison of efficacy with fluences immediately above and below the purpura threshold. Dermatol Surg. 2003;29:681-685.
5. Schroeter CA, Haaf-von Below S, Neumann HA. Effective treatment of rosacea using intense pulsed light systems. Dermatol Surg. 2005;31:1285-1289.
6. Clark SM, Lanigan SW, Marks R. Laser treatment of erythema and telangiectasia associated with rosacea. Lasers Med. 2002;17:26-33.
7. Alster T, Anderson RR, Bank DE, et al. The use of photodynamic therapy in dermatology: Results of a consensus conference. J Drugs Dermatol. 2006;5:140-154.
8. Rohrer TE, Chatrath V, Iyengar V. Does pulse stacking improve the results of treatment with variable-pulse pulsed-dye lasers? Dermatol Surg. 2004;30:163-167.
9. Mark KA, Sparacio RM, Voigt A, et al. Objective and quantitative improvement of rosacea-associated erythema after intense pulsed light treatment. Dermatol Surg. 2003;29:600-604.
10. Del Rosso JQ, Webster GF, Jackson M, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol. 2007;56:791-802.
11. Dahl MV, Katz HI, Krueger GG, et al. Topical metronidazole maintains remissions of rosacea. Arch Dermatol. 1998;134:679-683.
12. Bikowski JB. The pharmacologic therapy of rosacea: A paradigm shift in progress. Cutis. 2005;75(suppl 3):27-32.
13. Altinyazar HC, Koca R, Tekin NS, et al. Adapalene vs. metronidazole gel for the treatment of rosacea. Int J Dermatol. 2005;44:252-255.
14. Scheinfeld NS. Rosacea. Skinmed. 2006;5:191-194.
15. Scheinfeld N. When rosacea resists standard therapies. Skin & Aging. 2006;8:46-48.
16. Bamford JT, Tilden RL, Blankush JL, et al. Effect of treatment of Helicobacter pylori infection on rosacea. Arch Dermatol. 1999;135:659-663.
17. Herr H, You CH. Relationship between Helicobacter pylori and rosacea: It may be a myth. J Korean Med Sci. 2000;15:551-554.
18. Gorman CR, White SW. Rosaceiform dermatitis as a complication of treatment of facial seborrheic dermatitis with 1% pimecrolimus cream [letter]. Arch Dermatol. 2005;141:1168.
19. El Sayed F, Ammoury A, Dhaybi R, et al. Rosaceiform eruption to pimecrolimus [letter]. J Am Acad Dermatol. 2005;54:548-550.
20. Antille C, Saurat JH, Lübbe J. Induction of rosaceiform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment. Arch Dermatol. 2004;140:457-460.
21. Bernard LA, Cunningham BB, Al-Suwaidan S, et al. A rosacea-like granulomatous eruption in a patient using tacrolimus ointment for atopic dermatitis. Arch Dermatol. 2003;139:229-231.
22. Pelle MT, Crawford GH, James WD. Rosacea: II. therapy. J Am Acad Dermatol. 2004;51:499-512.
23. Wilkin JK. Rosacea: Pathophysiology and treatment. Arch Dermatol. 1994;130:359-362.
24. Daly TJ, Weston WL. Retinoid effects on fibroblast proliferation and collagen synthesis in vitro and on fibrotic disease in vivo. J Am Acad Dermatol. 1986;15 (4, pt 2):900-902.
25. Schmidt JB, Gebhart W, Raff M, et al. 13-cis-retinoic acid in rosacea. clinical and laboratory findings. Acta Derm Venereol. 1984;64:15-21.
26. Yamamoto O, Bhawan J, Solares G, et al. Ultrastructural effects of topical tretinoin on dermoepidermal junction and papillary dermis in photodamaged skin. a controlled study. Exp Dermatol. 1995;4: 146-154.